NCT04723030

The Transformation of Locally Advanced Pancreatic Cancer.

Carrilizumab Combined With Apatinib Mesylate and Radiotherapy and Chemotherapy for the Transformation of Locally Advanced Pancreatic Cancer.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy (paclitaxel (albumin binding) combined with gemcitabine and cisplatin) in the treatment of locally advanced pancreatic cancer in patients with locally advanced pancreatic cancer.

Detailed description

This trial is a prospective, observational, single-center, single-arm clinical research.Conversion treatment lasted for a total of 12 weeks, with one treatment cycle every two weeks.Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped

Conditions

• Locally Advanced Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)	Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy. Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week.

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-04-01
• Completion: 2023-04-01
• First posted: 2021-01-25
• Last updated: 2021-01-25

Locations

2 sites across 1 country: China